New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
05:05 EDTVNDAVanda Pharmaceuticals receives negative opinion from CHMP on Fanaptum
Vanda Pharmaceuticals announced that the European Medicines Agency's Committee for Medicinal Product for Human Use, or CHMP, has issued a negative opinion recommending against approval of Fanaptum for the treatment of schizophrenia in adult patients in the European Union. The CHMP was of the opinion that the benefits of Fanaptum did not outweigh its risks and recommended against marketing authorization at this point in time. Vanda intends to appeal this opinion and request a re-examination of the decision by the CHMP.
News For VNDA From The Last 14 Days
Check below for free stories on VNDA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 14, 2014
11:46 EDTVNDAOptions with decreasing implied volatility
Subscribe for More Information
August 13, 2014
10:33 EDTVNDAOptions with decreasing implied volatility
Options with decreasing implied volatility: RPTP ARWR ZU ICPT MNKD UBNT OLED RAX UVXY VNDA
August 12, 2014
11:15 EDTVNDAOptions with decreasing implied volatility
Subscribe for More Information
August 11, 2014
11:28 EDTVNDAOptions with decreasing implied volatility
Options with decreasing implied volatility: GRPN MNKD UBNT OLED ZU RPTP SALE UNXL FEYE VNDA
06:03 EDTVNDAVanda pullback a buying opportunity, says Piper Jaffray
Piper Jaffray recommends using the post-earnings pullback in shares of Vanda Pharmaceuticals as a buying opportunity. Piper says Hetlioz is launching well and that it sees no reason to back off its bullish stance or $25 price target. The firm reiterates an Overweight rating on the name.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use